AADI

Aadi Biosciences, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website aadibio.com
Employees(FY) 88
ISIN US00032Q1040

Performance

+40.66%

+53.39%

+85.25%

+110.56%

+67.82%

YTD

+64.56%

Profile

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Advanced Technical Analysis

Technical Analysis of AADI 2024-12-20

The stock exhibits a strong bullish sentiment, highlighted by a Moving Average Score of 96, indicating robust upward momentum, complemented by a Technical Score of 80. While the Oscillators Score of 63 suggests some potential consolidation, the overall indicators point towards a favorable outlook for the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AADI

Stock Rank

Recent News & Updates

2024-12-19 05:30
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO and $100 Million PIPE Financing(Prnewswire)
2024-11-05 19:00
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update(Prnewswire)
2024-10-30 04:05
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update(Prnewswire)
2024-08-20 05:00
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates(Prnewswire)
2024-08-06 20:00
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update(Prnewswire)
2024-07-31 04:05
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update(Prnewswire)
2024-07-05 01:07
3 Russell 2000 Stocks to Sell in July Before They Crash & Burn(Investorplace)
2024-05-29 04:05
Aadi Bioscience to Participate in the Jefferies Healthcare Conference(Prnewswire)
2024-05-23 05:30
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting(Prnewswire)
2024-05-09 01:52
Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-08 00:53
AADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-07 20:00
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update(Prnewswire)
2024-04-30 20:01
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update(Prnewswire)
2024-04-08 20:00
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting(Prnewswire)
2024-04-02 21:40
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?(Zacks)
2024-03-17 21:40
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?(Zacks)
2024-03-16 20:00
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)(Prnewswire)
2024-03-14 22:43
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-12 21:05
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates(Zacks)
2024-03-12 20:00
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update(Prnewswire)
2024-03-05 19:00
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update(Prnewswire)
2024-03-05 03:30
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024(Prnewswire)
2024-03-01 03:08
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO for the Treatment of Malignant PEComa(Prnewswire)
2024-02-26 03:05
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference(Prnewswire)
2024-01-26 03:05
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium(Prnewswire)
2024-01-19 03:05
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium(Prnewswire)
2023-12-14 20:14
Why Is Aadi Bioscience (AADI) Stock Down 56% Today?(Investorplace)
2023-12-14 03:05
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations(Prnewswire)
2023-11-07 19:46
Aadi Bioscience Q3 Loss Per Share Narrows(Rttnews)
2023-11-07 19:00
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update(Prnewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.